New clinical data from the wide-ranging CATIE study of schizophrenia drugs suggests that Novartis’ long-in-the-tooth Clozaril is more effective than rival drugs as a second-line therapy. New clinical ...

To earn CME related to this news article, click here. February 25, 2009 — The US Food and Drug Administration (FDA) has approved safety labeling revisions to warn of the risk for upper ...

Novartis is reported to be weighing the sale of its Ritalin, Clozaril and Exelon drugs as the Swiss giant cuts back on treatments for the central nervous system in favor of generics and other products ...

Aug. 31, 2005 -- The U.S. Food and Drug Administration (FDA) approved in May and June revisions to safety labeling to advise that oral vancomycin is considered the treatment of choice for severe ...

The first of the atypical antipsychotics, clozapine (Novartis’ Clozaril), could be a more than useful third-line treatment for schizophrenia in children and adolescents, a US study suggests. The first ...

TORONTO and MONTREAL, Sept. 9, 2015 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company"), a Canadian specialty pharmaceutical company dedicated to acquiring and marketing legacy branded ...